Critical Care Volume 5 Issue 6 |
Viewing options:Associated material:Related literature:- Articles citing this article
- Other articles by authors
- Related articles/pages
Tools:Post to:
|
ResearchAcute hemodynamic effects of inhaled nitric oxide, dobutamine and a combination of the two in patients with mild to moderate secondary pulmonary hypertensionCarmine D Vizza1, Giorgio Della Rocca2 , Di Angelo Roma1, Carlo Iacoboni1, Federico Pierconti2, Federico Venuta3, Erino Rendina3, Giovanni Schmid1, Paolo Pietropaoli2 and Francesco Fedele1 1Department of Cardiovascular and Respiratory Sciences, University of Rome 'La Sapienza', Rome, Italy 2Department of Anesthesiology, University of Rome 'La Sapienza', Rome, Italy 3Department of Thoracic Surgery, University of Rome 'La Sapienza', Rome, Italy author email corresponding author email
Critical Care 2001,
5:355-361doi:10.1186/cc1069
|
|
| Published: |
9 October 2001 |
Abstract
Introduction
The use of low-dose dobutamine to maintain hemodynamic stability in pulmonary hypertension may have a detrimental effect on gas exchange. The aim of this study was to investigate whether inhaled nitric oxide (INO), dobutamine and a combination of the two have beneficial effects in patients with end-stage airway lung disease and pulmonary hypertension.
Method
Hemodynamic evaluation was assessed 10 min after the administration of each drug and of their combination, in 28 candidates for lung transplantation.
Results
Administration of INO caused a reduction in mean pulmonary arterial pressure (MPAP), an increase in PaO2 with a significant reduction in venous admixture effect (Qs/Qt).Dobutamine administration caused an increase in cardiac index and MPAP, with a decrease in PaO2 as a result of a higher Qs/Qt. Administration of a combination of the two drugs caused an increase in the cardiac index without MPAP modification and an increase in PaO2 and Qs/Qt.
Conclusion
Dobutamine and INO have complementary effects on pulmonary circulation. Their association may be beneficial in the treatment of patients with mild to moderate pulmonary hypertension. |